v3.22.2.2
Stockholders' Equity
12 Months Ended
Jun. 30, 2022
Stockholders Equity  
Stockholders' Equity

5. STOCKHOLDERS’ EQUITY

On December 8, 2021, our board of directors authorized the amended and restated Certificate of Incorporation which increased the total authorized shares of common stock from 50,000,000 to 60,000,000 shares. As of June 30, 2022, and June 30, 2021, the Company had 31,930,000 and 31,231,000 shares of common stock issued and outstanding, respectively.

Common Stock

We have reserved shares of common stock for issuance as of June 30, 2022 as follows:

    

Reserved

Stock

Options

Stock options outstanding

 

5,443,928

Stock available for future grants or issuance:

 

2005 Stock Incentive Plan

679,790

2005 Management Stock Option Plan

71,983

2017 Employee Stock Purchase Plan

1,097,360

Total reserved shares of common stock for issuance

 

7,293,061

Preferred Stock

We are authorized to issue 5,000,000 shares of preferred stock with a par value of $0.001 per share. As of June 30, 2022 and 2021, no shares of preferred stock are issued or outstanding. Our board of directors has the authority, without further action by our stockholders, to issue up to 5,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares

constituting any series or the designation of such series, any or all of which may be greater than the rights of the common stock.

2005 Management Stock Option Plan

In May 2005, our board of directors adopted the 2005 Management Stock Option Plan (2005 Management Plan) which provides for the grant of non-statutory stock options to directors, officers and key employees of eGain and its subsidiaries. Our board extended the expiration date of the 2005 Management Plan to September 30, 2024. Options under the 2005 Management Plan are granted at a price not less than 100% of the fair market value of the common stock on the date of grant. Options granted under the 2005 Management Plan are subject to eGain’s right of repurchase, whose right shall lapse with respect to one-forty-eighth (1/48th) of the shares granted to a director, officer or key employee for each month of continuous service provided by such director, officer or key employee to eGain. The options granted under this plan are exercisable for up to ten years from the date of grant.

The following table represents the activity under the 2005 Management Plan:

    

Shares

    

    

Weighted

Available for

Options

Average

Grant

Outstanding

Exercise Price

Balance as of June 30, 2020

 

68,649

1,278,517

$

3.58

Options Granted

 

$

Options Exercised

 

(106,000)

$

4.30

Options Forfeited / Expired

 

$

Balance as of June 30, 2021

 

68,649

1,172,517

$

3.51

Options Granted

$

Options Exercised

(342,466)

$

4.08

Options Forfeited / Expired

3,334

(3,334)

$

1.75

Balance as of June 30, 2022

71,983

826,717

$

3.29

2005 Stock Incentive Plan

In March 2005, our board of directors adopted the 2005 Stock Incentive Plan which provides for the grant of stock options to eGain’s employees, officers, directors and consultants. Our board extended the expiration date of the 2005 Stock Incentive Plan to September 30, 2024 and made certain other changes. Options granted under the 2005 Stock Incentive Plan are non-qualified stock options. Non-qualified stock options may be granted to employees with exercise prices of no less than the fair value of the common stock on the date of grant. The options generally vest ratably over a period of four years and expire no later than ten years from the date of grant. During the fiscal year ended June 30, 2022, we have increased our number of authorized shares available for grant by 3,000,000 shares.

The following table represents the activity under the 2005 Stock Incentive Plan:

    

Shares

    

    

Weighted

Available for

Options

Average

Grant

Outstanding

Exercise Price

Balance as of June 30, 2020

 

1,073,386

1,607,449

$

5.60

Options Granted

 

(207,700)

207,700

$

12.07

Options Exercised

 

(173,313)

$

4.41

Options Forfeited / Expired

 

78,841

(78,841)

$

8.69

Balance as of June 30, 2021

 

944,527

1,562,995

$

6.44

Shares Added

3,000,000

$

Options Granted

(3,607,661)

3,607,661

$

11.18

Options Exercised

(210,521)

$

3.52

Options Forfeited / Expired

342,924

(342,924)

$

10.75

Balance as of June 30, 2022

679,790

4,617,211

$

9.96

During the fiscal year ended June 30, 2022, we granted 71,100 stock options to consultants.

The following table summarizes information about stock options outstanding and exercisable under all stock option plans as of June 30, 2022:

Options Outstanding

Options Exercisable

Weighted

Range of

Average

Weighted

Weighted

Exercise

Number of

Remaining

Average

Number of

Average

Prices

    

Shares

    

Contractual Life

    

Exercise Price

    

Shares

    

Exercise Price

$1.6-$2.13

14,980

4.70

$

1.80

14,980

$

1.80

$2.50

1,049,534

4.37

$

2.50

1,041,107

$

2.50

$3.4-$7.96

635,227

5.05

$

6.22

563,071

$

6.03

$8.2-$10.96

592,298

8.66

$

9.81

128,966

$

9.53

$11.05-$11.26

129,900

9.24

$

11.11

8,020

$

11.24

$11.36

2,701,365

9.13

$

11.36

511,788

$

11.36

$11.47-$13.75

286,174

7.82

$

12.40

137,426

$

12.90

$14.28

8,600

8.21

$

14.28

3,762

$

14.28

$14.40

3,550

6.12

$

14.40

3,402

$

14.40

$19.11

22,300

7.75

$

19.11

10,166

$

19.11

$1.6-$19.11

5,443,928

7.60

$

8.94

2,422,688

$

6.29

The summary of options vested and exercisable as of June 30, 2022 comprised:

    

    

    

Weighted

Average

Weighted

Aggregate

Remaining

Number of

Average

Intrinsic

Contractual

Shares

Exercise Price

Value

Term

Options outstanding

    

5,443,928

$

8.94

$

10,098,695

7.60

Fully vested and expected to vest options

 

5,173,999

$

8.83

$

10,072,808

7.52

Options exercisable

 

2,422,688

$

6.29

$

9,806,115

5.70

The aggregate intrinsic value in the preceding table represents the total intrinsic value based on stock options with a weighted average exercise price less than our closing stock price of $9.75 as of June 30, 2022 that would have been

received by the option holders, had they exercised their options on June 30, 2022. The total intrinsic value of stock options exercised was $4.3 million and $2.0 million during fiscal years 2022 and 2021, respectively.

Stock-Based Compensation

We account for stock-based compensation in accordance with ASC 718, Compensation—Stock Compensation. Under the fair value recognition provisions of ASC 718, stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period. Stock-based compensation expense consists of expenses for stock options and our employee stock purchase plan (ESPP).

2017 Employee Stock Purchase Plan

In October 2017, our board of directors adopted the 2017 Employee Stock Purchase Plan (ESPP) which provided eligible employees the option purchase the Company’s common stock through payroll deductions at a price equal to 85% of the lower of the fair market value at the entry date of the applicable offering period or at the end of each applicable purchasing period. The offering period, meaning a period with respect to which the right to purchase shares of our common stock may be granted under the ESPP, will not exceed twenty-seven months and consist of a series of six-month purchase periods. Eligible employees may join the ESPP at the beginning of any six-month purchase period. Under the terms of the ESPP, employees can choose to have between 1% and 15% of their base earnings withheld to purchase the Company’s common stock. On December 17, 2021, our board of directors authorized an additional 600,000 shares of common stock to be available for issuance under ESPP. As of June 30th, 2022 we have 1,097,360 reserved stock available for issuance under ESPP.

Determining the fair value of the stock-based awards at the grant date requires significant judgment and the use of estimates, particularly surrounding Black-Scholes valuation assumptions such as stock price volatility and expected option term.

The table below summarizes the effect of stock-based compensation (in thousands):

Fiscal Year Ended June 30,

    

2022

    

2021

Non-cash stock-based compensation expense

$

(11,380)

$

(1,700)

Income tax expense

 

(102)

 

(51)

Net (loss) income effect

$

(11,482)

$

(1,751)

The Company recognized $102,000 and $51,000 of tax expense related to stock-based compensation expense for eGain UK and Exony for the fiscal years ended June 30, 2022 and 2021, respectively. There is no income tax effect that has been recognized relating to the stock-based compensation expense in the US due to full valuation allowance.

Total stock-based compensation includes expense related to non-employee awards of $232,000 and $47,000 during the fiscal years ended June 30, 2022 and 2021, respectively.  

Total stock-based compensation includes expense related to the ESPP of $457,000 and $473,000 during the fiscal years ended June 30, 2022 and 2021, respectively.

  

We utilized the Black-Scholes valuation model for estimating the fair value of the stock-based compensation of options granted. All shares of our common stock issued pursuant to our stock option plans are only issued out of an authorized reserve of shares of common stock, which were previously registered with the Securities and Exchange Commission on a registration statement on Form S-8.

During the fiscal years ended June 30, 2022 and 2021, there were 3,607,661 and 207,700 options granted, respectively, with a weighted average grant date fair value of $5.83 and $6.60, per share, respectively.

We used the following assumptions as inputs into the Black-Scholes valuation model to estimate the fair value of the options granted:

Fiscal Year Ended June 30,

    

2022

2021

Dividend yield

 

Expected volatility

 

70

%  

72

%  

Average risk-free interest rate

 

1.01

%  

0.50

%  

Expected life (in years)

 

4.68

4.35

We used the following weighted-average assumptions as inputs to estimate the fair value of the ESPP stock purchase right:

Fiscal Year Ended June 30,

2022

2021

Dividend yield

Expected volatility

57

%  

69

%

Average risk-free interest rate

1.22

%  

1.27

%  

Expected term (in years)

0.50

0.50

Fair Value of grants per share

$

2.96

$

3.64

During the fiscal year ended June 30, 2022, employees were granted the right and purchased an aggregate of 145,715 shares pursuant to the 2017 ESPP. Compensation expense related to those purchase rights was $457,000 and $473,000 for the fiscal years ended June 30, 2022 and 2021, respectively.

As of June 30, 2022, unrecognized compensation expense related to purchase rights that will be recognized over a weighted average period of 0.42 years was $220,000.

The dividend yield of zero is based on the fact that we have never paid cash dividends and have no present intention to pay cash dividends. We determined the appropriate measure of expected volatility by reviewing historic volatility in the share price of our common stock, as adjusted for certain events that management deemed to be non-recurring and non-indicative of future events. The risk-free interest rate is derived from the average U.S. Treasury Strips rate.

We base our estimate of expected life of a stock option on the historical exercise behavior, and cancellations of all past option grants made by the Company during the time period which its common stock has been publicly traded, the contractual term of the option, the vesting period and the expected remaining term of the outstanding options.

In accordance with Accounting Standards Updates (ASU) 2016-09, Compensation—Stock Compensation: Improvements to Employee Share-Based Accounting, we elected to continue to estimate forfeitures in the calculation of stock-based compensation expense.

The following table summarizes stock-based compensation expense relating to stock options for the years ended June 30, 2022 and 2021, respectively (in thousands):

Fiscal Year Ended June 30,

2022

2021

Cost of revenue

$

2,916

$

222

Research and development

2,797

347

Sales and marketing

2,248

501

General and administrative

2,962

157

Total

$

10,923

$

1,227

Total unamortized compensation cost, net of forfeitures, for all options granted but not yet vested as of June 30, 2022 was $11.8 million which is expected to be recognized over the weighted average period of 1.64 years.